These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26464707)

  • 1. Expression of CD151/Tspan24 and integrin alpha 3 complex in aid of prognostication of HER2-negative high-grade ductal carcinoma in situ.
    Romanska HM; Potemski P; Kusinska R; Kopczynski J; Sadej R; Kordek R
    Int J Clin Exp Pathol; 2015; 8(8):9471-8. PubMed ID: 26464707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers.
    Romanska HM; Potemski P; Krakowska M; Mieszkowska M; Chaudhri S; Kordek R; Kubiak R; Speirs V; Hanby AM; Sadej R; Berditchevski F
    Br J Cancer; 2015 Nov; 113(9):1350-7. PubMed ID: 26418423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of CD151/Tspan24 from the complex with integrin α3β1 in invasive front of the tumour is a negative predictor of disease-free survival in oral squamous cell carcinoma.
    Romanska HM; Potemski P; Collins SI; Williams H; Parmar S; Berditchevski F
    Oral Oncol; 2013 Mar; 49(3):224-9. PubMed ID: 23099281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrin α3β1-CD151 complex regulates dimerization of ErbB2 via RhoA.
    Novitskaya V; Romanska H; Kordek R; Potemski P; Kusińska R; Parsons M; Odintsova E; Berditchevski F
    Oncogene; 2014 May; 33(21):2779-89. PubMed ID: 23792450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ductal carcinoma in situ and ductal carcinoma in situ with microinvasion: correlation of FDG uptake with histological and biological prognostic factors.
    Seo YY; Yoo IR; Park SY; Oh JK; Kim SH; Sohn HS
    Breast Cancer; 2017 May; 24(3):353-361. PubMed ID: 27312540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS).
    Altintas S; Toussaint J; Durbecq V; Lambein K; Huizing MT; Larsimont D; Van Marck E; Vermorken JB; Tjalma WA; Sotiriou C
    Breast J; 2011; 17(4):343-51. PubMed ID: 21645166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation.
    Oka K; Suzuki T; Onodera Y; Miki Y; Takagi K; Nagasaki S; Akahira J; Ishida T; Watanabe M; Hirakawa H; Ohuchi N; Sasano H
    Int J Cancer; 2011 Apr; 128(8):1770-82. PubMed ID: 20533549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance.
    Van Bockstal MR; Wesseling J; Lips EH; Smidt M; Galant C; van Deurzen CHM
    Breast Cancer Res; 2024 Aug; 26(1):125. PubMed ID: 39192322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
    Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
    Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
    Steinman S; Wang J; Bourne P; Yang Q; Tang P
    Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
    Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
    BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of HER2 protein examination in ductal carcinoma in situ.
    Horimoto Y; Tokuda E; Arakawa A; Kosaka T; Saito M; Kasumi F
    J Surg Res; 2011 May; 167(2):e205-10. PubMed ID: 20018297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.